Reduce the risk of disease progression by 78%, multi-kinase inhibitors receive FDA priority review qualification

On August 5, 2021, Exelixis announced that the US FDA has granted its multi-kinase inhibitor cabozantinib (cabozantinib, English trade name Cabometyx) supplementary new drug application (sNDA) priority review qualification for the treatment of 12-year-old and Patients with differentiated thyroid cancer (DTC) above

Cabozantinib is an oral small molecule tyrosine kinase inhibitor that can inhibit the activities of c-Met, VEGFR2, and AXL and RET

This multi-center, randomized, double-blind, placebo-controlled phase 3 clinical trial enrolled 300 patients who had experienced disease progression after receiving up to two vascular endothelial growth factor receptor (VEGFR) targeted therapies in the past

Based on trial data, in February 2021, the US FDA granted cabozantinib breakthrough therapy designation as a potential treatment option for patients with DTC who have progressed after previous treatment and are refractory to radioactive iodine

Cancerous thyroid tumors include differentiated, medullary, and undifferentiated types.

Note: The original text has been deleted

Reference materials:

[1] Exelixis Announces US FDA Accepts for Priority Review the Supplemental New Drug Application for Cabozantinib® (Cabotinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer.